Clinical Study of Combo, Avelumab and Defactinib, in Advanced Ovarian Cancer Begins

Clinical Study of Combo, Avelumab and Defactinib, in Advanced Ovarian Cancer Begins
A Phase 1/2 clinical trial evaluating the investigational drugs avelumab, a PD-L1 inhibitor, and defactinib, a FAK inhibitor, in patients with advanced ovarian cancer has dosed its first patient, Verastem announced. The study is expected to enroll up to 100 patients at possibly 15 sites across the U.S. It is currently enrolling participants, and information is available

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , , , , .

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

Leave a Comment

Your email address will not be published. Required fields are marked *